Lab21 appoints new CEO

11-07-2007: Lab21 has announced the appointment of Graham Mullis as its new CEO. Graham has held executive positions at FTSE and Nasdaq listed medical device companies including 1-800 Contacts Inc and Biocompatibles International PLC and pharmaceutical roles at Hoechst Roussel Ltd and R P Scherer Ltd. He has experience in successfully launching new businesses and technologies in healthcare markets, with IPO and extensive M&A experience at a variety of medical and pharmaceutical companies. Graham has an MBA from Warwick Business School and BSc in Biochemistry with Physiology from Southampton University.

Graham joins Lab21 from Optivue Ltd, a company formed to develop and license pharmaceutical & medical device applications in optical products, where he is a co-founder.

Watchlist

This is where you can add this news to your personal favourites

On my watchlist

Facts, background information, dossiers

biochemistry

More about Lab21

News

Lab21 acquires NPTech Ltd and appoints corporate advisors for European M&A activity

Lab21 has acquired NPTech Ltd, an independent clinical laboratory company providing diagnostic testing services for the NHS and private healthcare providers in the UK and parts of Europe. The acquisition of NPTech, in an undisclosed financial transaction, significantly broadens Lab21's rang ... more

Lab21 appoints new CEO

Lab21 has announced the appointment of Graham Mullis as its new CEO. Graham has held executive positions at FTSE and Nasdaq listed medical device companies including 1-800 Contacts Inc and Biocompatibles International PLC and pharmaceutical roles at Hoechst Roussel Ltd and R P Scherer Ltd. ... more